KOC
SRPT icon

Koss-Olinger Consulting’s Sarepta Therapeutics SRPT Stock Holding History

Koss-Olinger Consulting’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,500
Closed -$972K – 272
2021
Q2 		$972K Sell
12,500
-5,000
-29% -$379K 0.14% 89
2021
Q1 		$1.3M Buy
+17,500
New +$1.61M 0.22% 49

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Koss-Olinger Consulting's SRPT Position: Q3 2021 in Review

Koss-Olinger Consulting sold out of Sarepta Therapeutics (SRPT) in Q3 2021, closing a stake of 12,500 shares — an estimated $972K sold.

Koss-Olinger Consulting first reported a position in SRPT in Q1 2021 and held it in 2 quarters. The position peaked at $1.3M in Q1 2021. 306 funds tracked by Wall St. Rank hold SRPT as of Q3 2021.

  • Koss-Olinger Consulting reported no remaining Sarepta Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Koss-Olinger Consulting sold 12,500 Sarepta Therapeutics shares in Q3 2021, an estimated $972K.
  • Koss-Olinger Consulting first reported a position in Sarepta Therapeutics in Q1 2021 and held it in 2 quarters.
  • Koss-Olinger Consulting's Sarepta Therapeutics position peaked at $1.3M in Q1 2021.
  • 306 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2021.

Based on Koss-Olinger Consulting's 13F filing for Q3 2021, filed 9 Nov 2021.